You just read:

Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis

News provided by

Protagonist Therapeutics, Inc.

Mar 26, 2018, 06:45 ET